Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envoy Medical, Inc. filings document the public-company disclosures of a hearing health medical technology issuer with Class A common stock and Nasdaq-listed redeemable warrants under COCHW. Form 8-K reports include results of operations and financial condition, board and committee appointments, changes in the company’s certifying accountant, and related audit disclosures.
Proxy filings describe annual meeting proposals, director elections, independent auditor ratification, advisory executive compensation votes, amendments to the company’s equity incentive and employee stock purchase plans, and warrant or share-issuance matters under Nasdaq rules. The filing record also identifies Envoy Medical as an emerging growth company and discloses governance, capital-structure and risk-related subjects tied to its implantable hearing technology business.
Envoy Medical ownership disclosure: Bleichroeder and related filers report beneficial ownership of 7,839,000 shares of Class A common stock, equal to 9.99% of the class. The holding comprises 6,250,000 owned shares and 1,589,000 shares issuable upon exercise of warrants, with warrant exercises subject to a 9.99% Beneficial Ownership Limitation.
The filing states that without the 9.99% limit the filer would be deemed beneficial owner of 16,250,000 shares (including 10,000,000 warrants), or approximately 18.7% of outstanding common stock. Reporting persons are Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach.
Envoy Medical reported a Q1 2026 net loss of $4,351, slightly improved from $4,998 a year earlier, on very modest net revenue of $39. Operating expenses rose to $5,998, driven mainly by research and development for its fully implanted Acclaim cochlear implant.
Cash jumped to $25,251 from $3,739 at year-end 2025, after the February 2026 equity offering raised net proceeds of $27,782. That deal issued 47.9 million common shares, 27.1 million pre-funded warrants, and 120 million-plus Series A warrants.
Despite the stronger balance sheet, Envoy still discloses “substantial doubt” about its ability to continue as a going concern, citing ongoing losses and dependence on future financings and warrant exercises. The company ended the quarter with an accumulated deficit of $319,097 and 76,881,110 Class A shares outstanding.
Envoy Medical reported first quarter 2026 results and key milestones as it advances its fully implanted Acclaim cochlear implant toward FDA approval. Net revenue was $39,000, with an operating loss of $6.0 million and net loss of $4.4 million, or $0.08 per share attributable to common stockholders.
Cash rose to $25.3 million as of March 31, 2026, supported by an upsized public offering for up to $78.0 million, including $30.0 million in gross proceeds at closing and additional potential proceeds from milestone-linked warrants. The company completed enrollment of its U.S. pivotal trial, implanting the 56th and final patient, and early six‑month data from the first 10 patients showed no study-defined serious adverse events and improved CNC word recognition from 15.2% to 39.2%, supporting its path toward a planned PMA submission.
Envoy Medical, Inc. announced that its Board of Directors appointed Charles S. McKhann as a Class I director, with his initial term running until the company’s 2027 annual meeting of stockholders. In connection with his appointment, the Board size increased from six to seven members.
Mr. McKhann also joined the Board’s Compensation Committee and was granted stock options to purchase 100,000 shares of Class A Common Stock at an exercise price of $0.72 per share, vesting in 36 equal monthly installments. The Board determined that he qualifies as an independent director under Nasdaq and SEC standards.
Envoy Medical, Inc. director Chas McKhann received a grant of stock options covering 100,000 shares of Class A common stock. The options have an exercise price of $0.72 per share and expire on April 15, 2036.
Beginning May 15, 2026, these options vest pro rata on the 15th of each month over 36 consecutive months. After this grant, McKhann holds stock options for 100,000 underlying shares directly.
Envoy Medical, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to correct a typographical error in the consent of Grant Thornton LLP, its independent registered public accounting firm. The amendment also includes updated officer certifications under Section 302 of the Sarbanes-Oxley Act and makes no other changes to the original report.
The company reported an aggregate market value of approximately $12.7 million for Class A common stock held by non-affiliates as of its most recently completed fiscal quarter, and had 76,881,110 Class A shares outstanding as of March 20, 2026.
Envoy Medical is asking stockholders to approve several items at its May 12, 2026 annual meeting, including electing two Class III directors and ratifying EisnerAmper LLP as new auditor after dismissing Grant Thornton, whose prior reports included substantial doubt about the company’s ability to continue as a going concern and cited material weaknesses in internal control.
Stockholders will vote on an advisory say-on-pay proposal, a major amendment to the 2023 Equity Incentive Plan adding 6,000,000 shares for a total of 10,000,000, and an amendment to the Employee Stock Purchase Plan increasing its reserve by 1,200,000 to 1,500,000 shares. They are also asked to approve, under Nasdaq Listing Rule 5635(d), the exercisability of warrants issued in a February 12, 2026 financing, covering up to 123,750,000 shares of Class A common stock, which could significantly increase the company’s share count if fully exercised.
Envoy Medical, Inc. reported that its audit committee dismissed Grant Thornton LLP as its independent registered public accounting firm on March 25, 2026 and appointed EisnerAmper LLP to audit the fiscal year ending December 31, 2026.
Grant Thornton’s audit reports for the years ended December 31, 2025 and 2024 contained explanatory paragraphs expressing substantial doubt about Envoy Medical’s ability to continue as a going concern, but were not otherwise qualified or modified. The company states there were no disagreements with Grant Thornton and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Envoy Medical reported full year 2025 results showing it is still early-stage but making strategic progress. Net revenue was $241,000, slightly up from $225,000, while operating expenses of $22.5 million and other items drove a net loss of $23.8 million and a net loss attributable to common stockholders of $28.7 million, or $1.23 per share.
The company strengthened its balance sheet by extinguishing about $32 million of related-party term loan debt, supported by a $27.9 million deemed capital contribution. Total liabilities were $20.3 million and stockholders’ deficit improved to $12.2 million as of December 31, 2025, with cash of $3.7 million.
Operationally, Envoy advanced its fully implanted Acclaim cochlear implant program, receiving FDA approval to expand its pivotal trial to its final stage in 2025 and subsequently completing enrollment. After year-end it closed what it describes as a transformational capital raise led by institutional healthcare investors, positioning it to continue development toward a planned PMA submission.